Article
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2025
Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper A J, Ricciuti B, Digumarthy S, Alessi J V, Gogia P, Pecci F, Makarem M, Gandhi M M, Garbo E, Saini A, De Giglio A, Favorito V, Scalera S, Cipriani L, Marinelli D, Haradon D, Nguyen T, Haradon J, Voligny E, Vaz V, Gelsomino F, Sperandi F, Melotti B, Ladanyi M, Zhang J, Gibbons D L, Heymach J V, Nishino M, Lindsay J, Rodig S J, Pfaff K, Sholl L M, Wang X, Johnson B E, Jänne P A, Rekhtman N, Maugeri-Saccà M, Heist R S, Ardizzoni A, Awad M M, Arbour K C, Schoenfeld A J, Vokes N I, Luo J
Abstract excerpt
BACKGROUND: Approximately 10% of lung adenocarcinomas (LUADs) have mucinous histology (LUADMuc), which is associated with a light/absent smoking history and a high prevalence of KRAS mutations. We sought to characterize LUADMuc by comparing it with LUAD without mucinous histology (LUADnon-muc) and determine the relative benefit of current treatments. PATIENTS AND METHODS: Patients with LUAD from five institutions...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.